Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sirolimus, a new, potent immunosuppressive agent

P A Kelly1, S A Gruber, F Behbod

  • 1Division of Immunology and Organ Transplantation, University of Texas Medical School-Houston, 77030, USA.

Pharmacotherapy
|December 17, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nucleotide sequences of three distinct complementary DNA clones encoding rat class II major histocompatibility complex RT1.D beta-chain proteins.

Immunogenetics·1999
Same author

Localization of immunogenic and tolerogenic epitopes in the RT1.A1 alloantigen.

Transplantation proceedings·1999
Same author

Induction of tolerance by oral administration of a tolerogenic allochimeric donor/recipient class I MHC protein.

Transplantation proceedings·1999
Same author

Immunization with Escherichia coli-produced soluble MHC class I proteins induces accelerated rejection or prolonged survival of rat cardiac allografts.

Transplantation proceedings·1999
Same author

Recommendations concerning the introduction of generic formulations of cyclosporine.

Transplantation proceedings·1999
Same author

Considerations concerning generic formulations of immunosuppressive drugs.

Transplantation proceedings·1999

Sirolimus (SRL) effectively prevents renal transplant rejection by inhibiting T and B cell proliferation. Therapeutic monitoring via trough levels is feasible, but higher concentrations may increase adverse effects like cytopenias.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation

Background:

  • Sirolimus (SRL) is a potent immunosuppressant investigated for renal transplant rejection prophylaxis.
  • SRL inhibits T and B cell proliferation by blocking cytokine responses and cell cycle progression.
  • Therapeutic drug monitoring of SRL may be achieved using trough whole blood concentrations.

Purpose of the Study:

  • To evaluate the efficacy and safety of Sirolimus (SRL) in renal transplant recipients.
  • To explore the correlation between SRL concentrations and clinical outcomes, including rejection and adverse effects.
  • To assess the synergistic effects of SRL in combination with other immunosuppressants like cyclosporine (CsA).

Main Methods:

  • Phase III clinical trials investigating SRL for prophylaxis of renal transplant rejection.

Related Experiment Videos

  • Analysis of the correlation between SRL concentrations (area under the curve and trough levels) and clinical outcomes.
  • Evaluation of adverse effects associated with SRL, including thrombocytopenia, leukopenia, and lipid level changes.
  • Review of in vitro, animal, and clinical studies on the synergy between SRL and cyclosporine (CsA).

    • Main Results:

    • Trough SRL concentrations may allow for therapeutic monitoring.
    • SRL concentrations of 15 ng/ml or higher are associated with increased adverse effects.
    • The combination therapy of SRL and CsA reduced acute rejection episodes in Phase II trials.
    • SRL-CsA therapy allowed for corticosteroid withdrawal and reduced CsA dosages in nonblack patients.

    Conclusions:

    • Sirolimus (SRL) demonstrates potential in preventing renal transplant rejection.
    • Therapeutic drug monitoring of SRL via trough levels is a viable strategy.
    • Careful monitoring is required due to potential toxicities, especially at higher concentrations.
    • Combination therapy with SRL and CsA shows promise in improving transplant outcomes and reducing other immunosuppressants.